Press releaseGlobe Newswire
ANI Pharmaceuticals
ANIP · NASDAQ
$72.67+$0.11 (+0.15%)TodayMarket closed ·
Prev close $72.56
Latest news
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
- Press releaseGlobe Newswire
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
- NewsAvi Kapoor
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
- News
ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
- NewsStjepan Kalinic
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
- News
ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate.
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
- NewsVandana Singh
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
- News
ANI Pharmaceuticals Q4 Earnings Assessment
- News
ANI Pharmaceuticals Q4 Adj. EPS $2.33 Beats $2.00 Estimate, Sales $247.060M Beat $231.534M Estimate
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
- Press releaseGlobe Newswire
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Formation of "FutureVision Advisory Council" to Help Strategically Guide Ophthalmology and Retina Franchise
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Board Transition
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
- News
Examining the Future: ANI Pharmaceuticals's Earnings Outlook
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
- News
Earnings Preview For ANI Pharmaceuticals
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
- NewsAvi Kapoor
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
- Press releaseGlobe Newswire
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
- News
An Overview of ANI Pharmaceuticals's Earnings
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Press releaseGlobe Newswire
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.